Mesoblast (MEOBF) EPS (Basic) Growth (3y) (2017 - 2023)
Powered by 
Analysis
Mesoblast (MEOBF) EPS (Basic) Growth (3y) (2017 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.30 Bn | 9.45 Bn | 112.79 Mn | 51.67% |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.80 Bn | 3.51 Bn | 55.72 Mn | 39.50% |
| 4 | Legend Biotech | 3.69 Bn | 2.72 Bn | 251.50 Mn | 32.71% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 44.39% |
| 9 | Vericel | 1.98 Bn | 1.82 Bn | 56.40 Mn | 34.14% |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 32.13% |
| Dec 31, 2022 | 14.71% |
| Sep 30, 2022 | -32.87% |
| Jun 30, 2022 | 15.49% |
| Mar 31, 2022 | 13.08% |
| Dec 31, 2021 | 6.72% |
| Sep 30, 2021 | 3.67% |
| Jun 30, 2021 | 6.59% |
| Mar 31, 2021 | 1.81% |
| Dec 31, 2020 | -50.59% |
| Sep 30, 2020 | -13.05% |
| Mar 31, 2020 | -27.88% |
| Dec 31, 2019 | -3.37% |
| Sep 30, 2019 | 46.24% |
| Jun 30, 2019 | -34.13% |
| Mar 31, 2019 | 2.01% |
| Dec 31, 2018 | 8.77% |
| Sep 30, 2018 | -11.99% |
| Jun 30, 2018 | 22.28% |
| Mar 31, 2018 | 1.16% |